AGOURA HILLS, California , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda TM against COVID-19.
-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 AGOURA HILLS, Calif. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel Part 1 patient with COVID-19.
Featuring Global Experts in Ayurveda and Pharmacology December 16, 2020 7 AM PST- 10 AM EST - 8:30 PM IST Panel Discussion and Q & A to follow Agoura Hills, California , Dec. 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or “Oncotelic) (OTCQB.MATN) today announced that it is
--75% IMPROVEMENT BY DAY 2 ON ARTIVEDA™ COVID-19 AGOURA HILLS, California , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, provided development update for ARTIVeda TM /ArtiShield TM against
AGOURA HILLS, Calif. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September 30, 2020 (“Q3 2020”), as well as an update on its therapeutic development initiatives, including those
AGOURA HILLS, Calif. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today an agreement with Windlas Biotech Pvt. Ltd. of India (Windlas) to commercialize ARTIVeda ™ . ARTIVeda ™ is Mateon’s lead ethnobiology drug against
AGOURA HILLS, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Instituto Nacional de Salud (INS), the regulatory agency of Peru , to initiate the Company’s C001- Phase 2 clinical trial of
“Advancing Ayurveda Through Ethnobiology Drug Development” Topics Include Mateon’s ARTIShield ™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection AGOURA HILLS, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today
Dr. Kshirsagar will speak on ARTIShield™ at Delhi University on Oct 28, 2020 in his talk titled “Ayurveda concepts of Pandemic and Immunity” Dr. Kshirsagar is advisor to Mateon on its Ayurvedic product ARTIShield™ in a global clinical trial to treat COVID-19. AGOURA HILLS, Calif. , Oct.
AGOURA HILLS, Calif. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder Ejecutivo Nacional, the regulatory agency of Argentina, to initiate the Company’s Phase 2 clinical
